

Attorney Docket No.: 3951.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thim et al.

Serial No.: 09/528,644

Group Art Unit: 1647

Filed: 20 March 2000

Examiner: David Romeo

Confirmation No: 5698

For: Human Spasmolytic Polypeptide in Glycosylated Form

1647
#3
JAN 03 2001
TECH CENTER 1600/2900

RECEIVED

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

BOX DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Supplemental Information Disclosure Statement
2. Copies of References


is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on November 9, 2001

Sylvia Gonzalez
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 3951.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thim et al

Application No.: 09/528,644

Group Art Unit: 1647

Filed: March 20, 2000

Examiner: D. Romeo

For: Human Spasmolytic Polypeptide in Glycosylated Form

TECH CENTER 1600/2900
JAN 03 2001

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609.

The references are as follows:

1. WO 92/14837
2. DE 3808456 A1
3. J.U. Bowie., Science, Vol. 247, pages 1306-1310 (1990)
4. W. Hoffman., The Journal of Biological Chemistry Vol. 263., No. 16
Pages 7686-7690
5. M.D. Carr ., Biochemistry Vol. 31., No. 7., pages. 1998-2004 (1992)
6. K.H. Jorgensen et al., Regulatory Peptides. Vol. 3., pages 207-219
(1982)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This supplemental information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but before the mailing date of either a final action or a notice of allowance.

Accompanying this supplemental information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) for submission of a supplemental information disclosure statement under § 1.97(c) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: November 9, 2001

Richard E. Bork
Richard Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE